Uncover key drivers, emerging technologies, and competitive movements shaping the next generation tissue biomarkers market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Next Generation Tissue Biomarkers Market?

The next generation tissue biomarkers market size has experienced rapid expansion in recent years. It is anticipated to increase from $2.68 billion in 2024 to $3.03 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.1%. The market’s historical growth can be linked to the escalating demand for personalized medicine, the broader adoption of immunohistochemistry techniques, the increasing necessity for early disease detection, heightened healthcare spending, the proliferation of diagnostic imaging technologies, growing understanding of biomarker-based diagnostics, and an intensified concentration on companion diagnostics.

The next generation tissue biomarkers market size is projected to experience rapid growth in the coming years, with expectations to reach $4.89 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.7%. This expansion during the forecast period can be attributed to factors such as the growing demand for multiplex biomarker assays, the rising adoption of next-generation sequencing, increasing investment in cancer research, the broadening applications of digital pathology, the growing use of AI in diagnostics, a surge in clinical trials for targeted therapies, and the increasing availability of tissue-based genomic data. Major trends anticipated in this period include continued advancements in next-generation sequencing, the integration of artificial intelligence (AI) in digital pathology, the development of advanced mass spectrometry-based proteomics, innovations in ribonucleic acid biomarker detection technologies, and enhanced integration with cloud-based data platforms.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27363&type=smp

What Are The Primary Factors Supporting The Next Generation Tissue Biomarkers Market Expansion?

The increasing need for individualized medical care is projected to stimulate the expansion of the next generation tissue biomarkers market moving forward. Personalized medicine represents a healthcare strategy that customizes treatment based on an individual’s genetic makeup, lifestyle, and environmental factors. Its adoption is on the rise due to continuous advancements in genomic technologies, which facilitate highly specific and tailored treatment approaches. This demand for personalized medicine is fostering the development of next-generation tissue biomarkers, as they supply precise and individualized data necessary to adapt treatments to each patient’s distinct tissue profile. For instance, in February 2024, as reported by the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, a rise from six in 2022. The personalized treatments newly sanctioned for 2023 also encompassed seven cancer drugs and three for various other conditions. Therefore, the expanding demand for personalized medicine is propelling the growth of the next generation tissue biomarkers market.

Which Segments Define The Structure Of The Next Generation Tissue Biomarkers Market?

The next generation tissue biomarkers market covered in this report is segmented

1) By Type: Genomic Biomarkers, Proteomic Biomarkers, Epigenetic Biomarkers, Transcriptomic Biomarkers, Metabolomic Biomarkers

2) By Technology: Immunohistochemistry, Next-Generation Sequencing, Mass Spectrometry (Ms)-Based Proteomics, Spatial Biology Platforms, Digital Pathology And Artificial Intelligence Analysis, Other Technologies

3) By Application: Oncology, Companion Diagnostics, Drug Discovery And Development, Neurology, Other Applications

4) By End Use: Hospitals And Reference Labs, Pharma And Biotech Companies, Academic And Research Institutes, Contract Research Organizations

Subsegments:

1) By Genomic Biomarkers: Single Nucleotide Polymorphisms, Copy Number Variations, Gene Fusions

2) By Proteomic Biomarkers: Protein Expression Levels, Post-Translational Modifications, Protein-Protein Interactions

3) By Epigenetic Biomarkers: Histone Modification Patterns, Chromatin Remodeling Biomarkers, Non-Coding Ribonucleic Acid Regulation

4) By Transcriptomic Biomarkers: Long Non-Coding Ribonucleic Acids, Circular Ribonucleic Acids, Alternative Splicing Variants

5) By Metabolomic Biomarkers: Lipid Profiles, Amino Acid Signatures, Organic Acids

What Strategic Shifts And Innovations Are Influencing The Next Generation Tissue Biomarkers Market?

Leading companies in the next generation tissue biomarkers market are concentrating on creating advanced solutions, such as genomic diagnostic assays and sequencing solutions, to boost the accuracy, speed, and individualized approach to cancer diagnosis and treatment. These genomic-based diagnostic assays and sequencing solutions are tools and methods that analyze genetic data to identify disease-specific biomarkers, facilitating more precise and tailored strategies for diagnosis and therapy. For example, in August 2024, Illumina Inc., a US-based biotechnology company, obtained FDA approval for its TruSight Oncology Comprehensive test, along with two accompanying diagnostics, to swiftly connect cancer patients with targeted therapies. This test profiles over 500 genes from a single tissue sample, enabling exact treatment selection for various solid tumors. Furthermore, it automates biomarker detection and supports continuous deployment, considerably reducing turnaround times and improving clinical efficiency, showcasing a modern strategy for streamlining cancer diagnostics within a regulated context.

Who Are The Primary Market Leaders In The Next Generation Tissue Biomarkers Market?

Major companies operating in the next generation tissue biomarkers market are Roche Diagnostics, Thermo Fisher Scientific Inc., LabCorp., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., NanoString Technologies Inc., PathAI Inc., Biocartis Group NV, Personalis Inc., Ultivue Inc., Indica Labs Inc., Strata Oncology Inc., Genialis Inc., Alida Biosciences Inc., and Biofidelity Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/next-generation-tissue-biomarkers-global-market-report

What Regional Factors Are Accelerating Growth In The Next Generation Tissue Biomarkers Market?

North America was the largest region in the next generation tissue biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation tissue biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27363&type=smp

Browse Through More Reports Similar to the Global Next Generation Tissue Biomarkers Market 2025, By The Business Research Company

Nail Care Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nail-care-products-global-market-report

Nail Polish Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nail-polish-global-market-report

Smart Pneumatics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/smart-pneumatics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model